Sparsentan fda approval date?

See the DrugPatentWatch profile for Sparsentan

When did the FDA approve sparsentan?

FDA approval for sparsentan (brand name: Filspari) was announced on May 28, 2023. [1]

What did the FDA approve sparsentan for?

Sparsentan was approved for treatment of primary IgA nephropathy (IgAN) at risk of rapid disease progression. [1]

Has the approval date changed because of label updates?

The core FDA approval date remains May 28, 2023; later changes (if any) would be reflected as label updates, but they do not change the original FDA approval announcement date. [1]

Where can I verify the approval date?

You can verify the date through the FDA’s approval communication for sparsentan. [1]

Sources:
[1] https://www.fda.gov/news-events/press-announcements/fda-approves-filspari-sparsentan-primary-iga-nephropathy